[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521946":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":22,"responsibleParty":38,"collaborators":41,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Shandong University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Piperacillin Sodium and Tazobactam Sodium for Injection","Piperacillin\u002FTazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin\u002Ftazobactam, specific regimen based on clinical practice, without intervention.",[14],{"name":15,"affiliation":5,"role":16},"Wei Zhao, Ph.D","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","86053188383308","zhao4wei2@hotmail.com",[23],{"facility":24,"status":25,"city":26,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Shandong Provincial Hospital","RECRUITING","Jinan","China","CN",{"type":30,"coordinates":31},"Point",[32,33],116.99722,36.66833,{"lat":33,"lon":32},[36],{"name":37,"role":19,"phone":7,"phoneExt":7,"email":7},"Yonghui Yu",{"type":16,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Wei Zhao","Head of department of clinical pharmacy and pharmacology",[42],{"name":24,"class":43},"OTHER_GOV","100521946","population-pharmacokinetic-of-piperacillintazobactam-in-maternal-and-neonatal-populations-100521946",false,"NCT06076200","Population Pharmacokinetic of Piperacillin\u002FTazobactam in Maternal and Neonatal Populations","Population Pharmacokinetic of Piperacillin\u002FTazobactam in Maternal and Neonatal Populations With High Risk for EOS","Inclusion Criteria:\n\n* Patients over 18 years old;\n* Pregnant women whose baby are at high risk of developing early-onset sepsis after birth have indications to use preventive or therapeutic antibiotics, and the antibiotics used are PIP\u002FTAZO；\n* Patients and their families are fully aware of the research content and sign the informed consent form.\n\nExclusion Criteria:\n\n* Intolerance or serious adverse reactions to antibiotic use;\n* Patients who stopped using PIP\u002FTAZO more than 24 hours before delivery;\n* Receiving other systemic trial drugs;\n* There are other factors that the researchers think are not suitable for inclusion","FEMALE","18 Years",{"count":54,"type":55},50,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin\u002Ftazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin\u002Ftazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.",[59],"Early-Onset Neonatal Sepsis","2023-10-07",{"date":62,"type":63},"2023-10-10","ACTUAL",{"date":65,"type":55},"2023-09-30",{"date":67,"type":55},"2026-12-31",{"name":5,"class":6},1]